Month: August 2023

The second quarter of 2023 shows a 100 % growth in sales compared to the same period last year and strong increase in margins. Sales revenues ended at NOK 52.9m vs NOK 25.8m last year. The underlying growth is coming from both the ingredients business and finished products channels. In June, HBC announced the sale of patents to the newly established associated company, HBC Immunology Llc. (HBCI) in USA. The net proceeds from this sale of assets amounts to NOK 23.5m, resulting in total operating revenues in Q2 of NOK 76.4m. HBCI will focus on the discovery and development of peptides that normalize tumor micro-environments for co-treatment of prostate cancer, resulting in the improved performance of immunotherapies and chemotherapies. HBC holds 75 % shareholding in HBCI. Adjusted for the sale of assets to HBCI, operating revenues in the...

HONKARAKENNE OYJ         HALF-YEAR REPORT                 25 AUGUST 2023 AT 9:00 HONKARAKENNE OYJ HALF-YEAR REPORT 1 JANUARY TO 30 JUNE 2023 NET SALES AND OPERATING PROFIT DECLINED – ORDER BOOK AT PRE-PANDEMIC LEVEL Net sales for the first half of 2023 declined by 37% to EUR 23.0 million (H1 2022: 36.7). Operating profit excluding items affecting comparability deteriorated by EUR -1.9 million to EUR 0.3 million (EUR 2.2 million). The result for the review period was negative. At the end of the review period, the order book stood at EUR 28.0 million. January-June 2023Honkarakenne Group’s net sales in January–June amounted to EUR 23.0 million (H1 2022: 36.7). Net sales declined by 24% from the corresponding period of the previous year. Operating profit was slightly negative and amounted to EUR -0.0 million (2.2). Adjusted operating...

DIGITALIST GROUP PLC         HALF-YEAR REVIEW 25 AUGUST 2023, 9:00 AM DIGITALIST GROUP’S HALF-YEAR REVIEW, 1 JANUARY–30 JUNE 2023 SUMMARY April–June 2023 (comparable figures for 2022 in parentheses):Turnover: EUR 4.3 million (EUR 5.3 million), decrease: 17.9%. EBITDA: EUR -0.6 million (EUR -0.9 million), -13.7% of turnover (-17.0%). EBIT: EUR -0.8 million (EUR -1.3 million), -18.1% of turnover (-25.4%). Net income: EUR -1.2 million (EUR -2.1 million), -27.9% of turnover (-39.6%). Earnings per share (diluted and undiluted): EUR -0.00 (EUR -0.00).January–June 2023 (comparable figures for 2022 in parentheses):Turnover: EUR 8.9 million (EUR 10.4 million), decrease: 14.3%. EBITDA: EUR -0.9 million (EUR -1.4 million), -10.3% of turnover (-13.4%). EBIT: EUR -1.3 million (EUR -2.3 million), -15.0% of turnover (-22.0%). Net income:...

RESULTS FOR THE FIRST HALF OF THE YEAR The profitability of the Danish core business improved in the first half of the year, but the improvement was eclipsed by a considerable operating loss recorded by MT Højgaard International whose activities are being scaled down in a controlled process.Group revenue increased by 24% to DKK 4.9 billion, driven by double-digit growth in the Danish business units. Group operating profit before special items decreased by 40% to DKK 64 million. The Danish core business consisting of MT Højgaard Danmark, Enemærke & Petersen and MT Højgaard Property Development increased its operating profit by 39% to DKK 147 million, and the operating margin rose from 2.9% to 3.2%. MT Højgaard International’s operating profit before special items deteriorated, and the business unit recorded a loss of DKK 83...